Preliminary results from TRoMbone pave the way for a full randomized controlled trial.
The medication showed promise as correction and maintenance therapy in a phase 2b trial of non-dialysis CKD patients with anemia.
Study finds no decrease in the risk for mortality, myocardial infarction, or heart failure in the first 180 days.
Study supports the hypothesis that altered tubular phosphate handling drives the increase in serum phosphate during SGLT2 inhibition.
Many are calling for standard dialysis coverage for undocumented immigrants with end-stage renal disease.
Kidney cancer and some other cancers tied to obesity are increasing the most rapidly among individuals younger than 50.
Investigators found a U-shaped curve of mortality against ferritin/TSAT levels in patients without autosomal dominant polycystic kidney disease, but not in those with the disease.
In a study, having the single nucleotide polymorphism rs11063112 in fibroblast growth factor 23 was associated with a 32% greater risk for cardiovascular mortality.
In 2 studies, roughly a third of hemodialysis patients achieved within-range serum phosphate levels after converting to sucroferric oxyhydroxide from another phosphate binder.
Androgen deprivation therapy recipients had a significantly lower risk for autoimmune diseases overall and for Graves’ disease, uveitis, and psoriasis.
